Pharmacovigilance and Drug Safety Software Market Report 2026

The pharmacovigilance and drug safety software market size has grown rapidly in recent years. It will grow from $2.53 billion in 2025 to $2.86 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to increasing adverse drug reaction reporting, globalization of clinical trials, stringent drug safety regulations, growth in pharmaceutical production, rising post-marketing surveillance requirements.

The pharmacovigilance and drug safety software market size is expected to see rapid growth in the next few years. It will grow to $4.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to expansion of ai-driven signal detection, growth in biologics and specialty drugs, rising regulatory scrutiny, increasing outsourcing of pharmacovigilance services, demand for real-time safety analytics. Major trends in the forecast period include growing adoption of cloud-based pharmacovigilance platforms, increasing focus on real-world evidence monitoring, rising automation in adverse event reporting, expansion of integrated drug safety systems, higher demand for regulatory compliance solutions.

The increasing demand for personalized medicine is anticipated to drive the growth of the pharmacovigilance and drug safety software market in the coming years. Personalized medicine, also referred to as precision medicine, is a healthcare approach that customizes treatment decisions based on an individual’s genetic profile, biological factors, and lifestyle characteristics. The rising adoption of personalized medicine is driven by better treatment outcomes, improved prevention and early diagnosis, and increased cost efficiency. Pharmacovigilance and drug safety software supports personalized medicine by incorporating pharmacogenomics, real-time data analytics, and post-marketing surveillance to enhance patient safety, track individualized therapies, and reinforce risk management processes. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for rare disease patients in 2023, an increase from 6 approvals in 2022. Consequently, the growing demand for personalized medicine is fueling the expansion of the pharmacovigilance and drug safety software market.

Major companies operating in the pharmacovigilance and drug safety software market are concentrating on the development of advanced technologies such as cloud-based data lake platforms to reinforce adverse event detection, enhance regulatory adherence, and improve overall patient safety throughout clinical trials and post-marketing surveillance. A cloud-based data lake platform is a scalable, centralized solution that enables the storage and real-time analysis of large volumes of structured and unstructured safety data, supporting advanced analytics, AI/ML models, and more efficient case management within pharmacovigilance operations. For example, in December 2023, Thermo Fisher Scientific Inc., a US-based biotechnology company, introduced CorEvidence, a proprietary cloud-based data lake platform aimed at streamlining pharmacovigilance activities by enhancing safety data management and case processing efficiency, with a particular focus on supporting post-authorization safety studies in clinical research registries.

In April 2024, Qinecsa, a UK-based company, acquired Insife ApS for an undisclosed amount. This acquisition enhances Qinecsa’s end-to-end pharmacovigilance technology capabilities by incorporating Insife’s advanced safety software solutions into its digital pharmacovigilance ecosystem. It also strengthens Qinecsa’s position in the global pharmacovigilance market by broadening its technology portfolio and supporting its strategy to emerge as a leading provider of digital pharmacovigilance solutions. Insife ApS is a Denmark-based company specializing in pharmacovigilance software.

Major companies operating in the pharmacovigilance and drug safety software market are IQVIA, Oracle Corporation, ArisGlobal, RXLogix, Anju Software Inc., EXTEDO GmbH, Sarjen Systems Pvt Ltd, Ennov Group, AB Cube, Clinevo Technologies, Accenture plc, International Business Machines Corporation, Capgemini SE, Cognizant Technology Solutions, Wipro Limited, Genpact, Indegene Limited, PharmaLex, Deloitte Touche Tohmatsu Limited, Parexel.

North America was the largest region in the pharmacovigilance and drug safety software market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pharmacovigilance and drug safety software market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pharmacovigilance and drug safety software market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased costs for imported software infrastructure components, licensed platforms, and data hosting services used in pharmacovigilance and drug safety software systems. These impacts are most pronounced in Asia Pacific and emerging markets where vendors rely on cross border technology and cloud service providers. Rising tariff related expenses have influenced software pricing models, subscription costs, and implementation budgets for pharmaceutical companies. This has affected adoption timelines and upgrade decisions for compliance driven safety platforms. However, tariffs are also encouraging domestic software development, localized cloud deployments, and stronger regional digital health ecosystems over the long term.

The pharmacovigilance and drug safety software market research report is one of a series of new reports that provides pharmacovigilance and drug safety software market statistics, including pharmacovigilance and drug safety software industry global market size, regional shares, competitors with a pharmacovigilance and drug safety software market share, detailed pharmacovigilance and drug safety software market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacovigilance and drug safety software industry. This pharmacovigilance and drug safety software market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmacovigilance and drug safety software encompasses a range of digital solutions developed to track, evaluate, and document adverse drug reactions (ADRs) and other safety-related data linked to pharmaceutical and medical products. These tools are essential for safeguarding patient health and meeting regulatory requirements across the entire drug lifecycle, from clinical development through post-marketing monitoring.

The primary software types in pharmacovigilance and drug safety include adverse event reporting software, drug safety audit software, issue tracking software, and fully integrated software. Adverse event reporting software is intended to monitor, record, and manage adverse events associated with pharmaceutical products or medical devices. These solutions are available through on-premise and cloud-based delivery modes and are utilized by a range of end users, including pharmaceutical and biotechnology companies, contract research organizations, business process outsourcing firms, and others.

The pharmacovigilance and drug safety software market includes revenues earned by entities by signal detection and management tools, risk assessment, and management software. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.